Radical cure for falciparum malaria in co-endemic areas

恶性疟疾共流行地区的根治

• 批准号: nhmrc : GNT1154716
• 金额: $ 41.36万
• 依托单位国家: 澳大利亚
• 项目类别: International Collaborations
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/radical-cure-falciparum-endemic-areas/1378911
• 关键词: Radical; cure; falciparum; malaria; co

In areas co-endemic for the two main species of malaria P.falciparum and P.vivax, Primaquine the only drug currently available to treat the dormant liver forms of P. vivax malaria and therefore reduce relapses is only used in patients presenting with acute vivax malaria. However there is mounting evidence that P. falciparum infection increases the risk of P. vivax relapse. Therefore we propose to assess the benefit of administering Primaquine to patients with P. falciparum mono-infection.

在恶性疟原虫和间日疟原虫这两种主要疟疾的共同流行地区，伯马喹是目前唯一可用于治疗休眠肝型间日疟并因此减少复发的药物，仅用于出现急性间日疟的患者。然而，越来越多的证据表明，恶性疟原虫感染会增加间日疟原虫复发的风险。因此，我们建议评估使用伯克喹治疗单次感染恶性疟原虫的患者的益处。